A. Fred. B. Andy. C. Liz. D. Chris. 相关知识点: 试题来源: 解析 [答案]C 答案C 解析 细节理解题。根据倒数第三段中“She is positive that the flu vaccine will kill us all and that we should avoid it.”可知Liz不赞成用流感疫苗,故选C。反馈 收藏 ...
"I don't want any parent or grandparent to have to go through the trauma that we went through with our grandson with something that is entirely preventable, which RSV is." Mr Gwynne added that the vaccine "will ease enormous pressure on the NHS". Christine Burlison, whose baby became...
【题文】--- The research on the new bird flu virus vaccine is challenging and demanding. Who do you think can do the job?---___ my students have a try? A. Shall B. Must C. Will D. May. 相关知识点: 试题来源: 解析 【答案】A. 【解析】试题分析:考查情态动词:shall用于第一、三...
Promote the Flu Vaccine: The Last Thing We Need Is Another OutbreakBruno, RichardMaryland Medicine
This strain is included in this year’s vaccine so parents and caregivers are encouraged to vaccinate children. Vaccination against the flu may also reduce the risk of a severe outcome with other seasonal illnesses like RSV and strep A.
()17.-The research on the new flu virus vaccine is challenging and demanding. Who do you think can do the job?my students have a try? A. Shall B. Must C. Will D. May 相关知识点: 试题来源: 解析 7.A 【解析】句意:—关于新流感病毒疫苗的研究很有挑战 性,要求很高。 你认为谁能胜任...
Experts say the vaccine's poor performance is one reason why the United States has been suffering such anintense and deadly flu season. At least 63 children have died of flu nationwide so far this season. Nevertheless, health officials say getting the flu shot is still worthwhile. ...
——The research on the new flu virus vaccine is challenging and demanding. Who do you think can do the job? —— my students have a try? A. May B. Must C. Will D. Shall 相关知识点: 试题来源: 解析 make make与主语Parents之间是主动关系,且在情态动词can后, 应用原形,故填make。
---The research on the new flu virus vaccine is challenging and demanding. Who do you think can do the job? --- my students have a try?A.MayB.Must C.Will D.Shall
RSV in adults 60 years of age and older,” Stéphane Bancel, Moderna’s CEO, said in a statement. “These data are encouraging and represent the second demonstration of positive phase 3 trial results from our mRNA infectious disease vaccine platform after Spikevax, our COVID-19 vaccine....